Table 4

Proportion of patients cured classified by patient characteristics across countries*

India (Punjab State only)IndonesiaMyanmarNigeria (Nasarawa State only)Vietnam
% cured% cured% cured% cured% cured
N58 902/63 7462576/26671648/182636/391143/1151
Total %92.496.690.392.399.3
Sex
 Female95.0%96.5%92.2%92.9%98.5%
 Male91.0%96.6%88.4%90.9%99.5%
 Transgender100.0%
Age
 12–1984.5%†100.0%50.0%†100.0%†
 20–2987.5%94.6%93.9%100.0%†100.0%
 30–3993.4%97.7%93.0%90.0%99.0%
 40–4994.4%95.2%89.0%100.0%†99.5%
 50–5994.4%95.9%89.5%100.0%100.0%
 60–6993.7%97.6%91.2%66.7%†100.0%
 70+94.3%98.1%90.2%100.0%†96.0%
 Missing93.6%95.5%
Family history of HCV
 Yes97.9%91.4%100.0%†
 None Reported92.4%90.1%92.1%
History of injecting drugs
 Yes84.6%96.0%86.1%92.3%99.6%
 None reported92.6%96.8%90.8%99.1%
Known HIV coinfection
 Yes83.2%97.0%89.7%100.0%†99.6%
 No92.5%96.4%90.6%92.1%99.1%
Known HBV coinfection
 Yes92.1%66.7%†98.2%
 No92.4%90.2%94.4%99.4%
Cirrhosis
 Compensated93.0%90.0%99.2%
 Decompensated93.7%86.4%100.0%
 Cirrhotic (no additional information)91.5%97.0%100.0%†
 Non-cirrhotic92.4%96.4%90.7%91.7%99.3%
 Missing100.0%†
Treatment regimen
 SOF/DCV92.1%96.5%90.3%92.3%99.5%
 SOF/DCV+RBV81.0%97.7%99.0%
 SOF/VEL91.7%
 SOF/VEL+RBV94.4%
 Other86.4%96.7%
Treatment duration
 12 weeks92.2%96.4%90.1%91.7%99.3%
 24 weeks93.9%97.0%90.5%100.0%†100.0%
 Other94.2%100.0%†
Year of treatment initiation
 201694.2%
 201791.4%97.8%90.1%100.0%†99.1%
 201893.4%95.6%91.2%87.5%99.5%
 201990.8%96.7%100.0%†100.0%†
 202090.8%96.7%
 202176.9%96.1%
  • *Among those who completed SVR12 testing.

  • †Sample size was <10 people in this category.

  • DCV, daclatasvir; HBV, hepatitis B virus; HCV, hepatitis C virus; RBV, ribavirin; SOF, sofosbuvir; VEL, velpatasvir.